highlight
function
structur
character
inhibitor
inhibitor
bind
pocket
enzym
inhibitor
exhibit
high
degre
select
rel
dub
summari
deubiquitin
enzym
dub
garner
signific
attent
drug
target
last
year
excit
stem
larg
part
power
abil
dub
inhibitor
promot
degrad
oncogen
protein
especi
protein
challeng
directli
target
stabil
dub
famili
member
highli
optim
wellcharacter
dub
inhibitor
thu
becom
highli
sought
tool
report
dub
inhibitor
howev
polypharmacolog
agent
possess
weak
micromolar
potenc
toward
primari
target
limit
util
target
valid
mechan
studi
due
lack
highresolut
dub
smallmolecul
ligand
complex
structur
structureguid
optim
effort
report
mammalian
dub
report
smallmolecul
ubiquitinspecif
proteas
usp
famili
dub
costructur
rapid
design
potent
select
inhibitor
guid
structur
interestingli
compound
noncoval
activesit
inhibitor
member
evolutionarili
conserv
structur
distinct
new
famili
deubiquitin
enzym
studi
provid
optim
wellcharacter
probe
studi
normal
diseas
biolog
furthermor
lend
valid
notion
potent
select
activesit
inhibitor
dub
achiev
ubiquitin
protein
attach
substrat
protein
posttransl
via
isopeptid
bond
format
ubiquitin
ctermin
glycin
substrat
lysin
side
chain
komand
rape
linear
branch
polyubiquitin
chain
assembl
via
attach
anoth
molecul
ubiquitin
one
seven
lysin
ntermin
methionin
ubiquitin
pickart
fushman
ubiquitin
attach
substrat
protein
coordin
action
ubiquitinactiv
conjug
ligat
enzym
remov
famili
proteas
known
deubiquitin
enzym
dub
first
recogn
role
ubiquitin
system
control
protein
turnov
ciechanov
et
al
hershko
et
al
ubiquitin
tag
also
respons
signal
wide
rang
nondegrad
function
ubiquitin
affect
protein
activ
modul
conform
chang
complex
protein
ea
et
al
wu
et
al
suscept
addit
posttransl
modif
includ
phosphoryl
acetyl
hunter
zhang
et
al
zhao
et
al
cellular
local
li
et
al
combin
degrad
nondegrad
function
ubiquitin
coordin
wide
rang
cellular
process
includ
proteolysi
ciechanov
et
al
dna
repair
jackson
duroch
chromatin
remodel
weak
workman
receptor
signal
haglund
dikic
immun
malynn
zinngreb
et
al
among
other
surprisingli
aberr
ubiquitin
system
activ
link
diseas
includ
cancer
hoeller
dikic
pintofernandez
kessler
infect
isaacson
ploegh
maculin
et
al
neurodegener
ciechanov
brundin
ciechanov
kwon
relationship
ubiquitin
cancer
biolog
clinic
valid
food
drug
administr
approv
proteasom
inhibitor
bortezomib
multipl
myeloma
kane
et
al
approxim
human
dub
belong
six
distinct
famili
five
ubiquitinspecif
proteas
usp
ubiquitin
ctermin
hydrolas
uch
ovarian
tumor
proteas
otu
josephin
mindi
cystein
proteas
sixth
jammmpn
compos
zinc
metalloproteas
abdul
rehman
et
al
clagu
et
al
komand
et
al
komand
rape
mani
dub
link
physiolog
andor
pathophysiolog
function
exampl
involv
dnadamag
repair
kee
huang
role
chromatin
function
atanassov
et
al
report
stabil
oncogen
protein
cyclin
et
al
mutant
epiderm
growth
factor
receptor
byun
et
al
respect
dozen
apoand
ubiquitinbound
structur
solv
hu
et
al
johnston
et
al
komand
et
al
achiev
nonubiquitinbas
compound
davi
et
al
ratia
et
al
schlierf
et
al
notabl
smallmolecul
dub
complex
structur
lack
largest
mammalian
usp
famili
first
dub
inhibitor
dual
inhibitor
enter
clinic
trial
wang
et
al
overal
howev
dub
inhibitor
develop
still
earli
stage
approxim
dub
inhibitor
report
although
weak
multitarget
agent
darci
et
al
ndubaku
tsui
given
current
dearth
potent
select
inhibitor
skeptic
remain
whether
enzym
class
druggabl
manner
analog
protein
kinas
exampl
signific
hindranc
gener
potent
select
dub
inhibitor
lack
structureguid
optim
effort
one
exampl
structureguid
develop
dub
inhibitor
target
sar
dub
plpro
baezsanto
et
al
gener
compound
halfmaxim
inhibitori
concentr
ic
nm
exhibit
high
degre
select
rel
mammalian
dub
case
select
explain
signific
structur
differ
viral
mammalian
dub
breakthrough
xray
crystallographi
smallmolecul
dub
inhibitor
complex
potenti
enabl
rapid
develop
potent
select
inhibitor
mammalian
dub
dub
shown
involv
regul
myriad
cellular
process
includ
epigenet
cell
cycl
dna
repair
immun
viral
infect
tumorigenesi
also
known
hausp
herp
virusassoci
ubiquitinspecif
proteas
first
discov
protein
play
role
viral
lytic
growth
everett
et
al
interest
enzym
intensifi
implic
regul
degrad
tumor
suppressor
li
et
al
stabil
major
ligas
cummin
et
al
li
et
al
recent
sever
epigenet
modifi
includ
methyltransferas
wang
et
al
demethylas
du
et
al
fell
et
al
qin
et
al
acetyltransferas
dar
et
al
well
van
der
knaap
et
al
identifi
direct
target
notabl
target
includ
transcript
factor
tregulatori
treg
cell
link
dub
enzym
immun
respons
van
loosdregt
et
al
nmyc
stabil
neuroblastoma
cell
tavana
et
al
consist
regul
divers
substrat
biolog
process
emerg
drug
target
wide
rang
malign
includ
multipl
myeloma
chauhan
et
al
breast
cancer
wang
et
al
neuroblastoma
tavana
et
al
glioma
cheng
et
al
ovarian
cancer
zhang
et
al
close
analog
inhibitor
frequent
util
probe
function
structur
see
figur
exhibit
modest
potenc
ic
mm
equipot
inhibit
two
addit
dub
altun
et
al
ritorto
et
al
addit
modest
potenc
select
report
drawback
nitrothiophenebas
compound
includ
poor
solubl
gener
toxic
chen
et
al
addit
inhibitor
shown
figur
identifi
although
none
possess
featur
superior
signific
optim
effort
undertaken
aleo
et
al
colland
et
al
eldesoki
et
al
nicholson
et
al
reverdi
et
al
tanokashira
et
al
yamaguchi
et
al
report
structureguid
develop
nextgener
smallmolecul
probe
highresolut
smallmolecul
crystal
structur
enabl
us
rapidli
develop
highli
select
nm
inhibitor
lead
probe
furthermor
show
enantiom
less
potent
thu
serv
inact
control
compound
contrast
target
invari
catalyt
cystein
usp
dub
noncoval
activesit
inhibitor
demonstr
activeinact
inhibitor
pair
power
combin
studi
function
cellular
model
part
effort
identifi
chemic
start
point
develop
dub
inhibitor
profil
inhibitori
activ
compound
report
peerreview
patent
literatur
activ
larg
panel
dub
ritorto
et
al
identifi
highli
select
inhibitor
structur
figur
report
patent
hybrigen
colland
gourdel
kessler
screen
inhibitori
activ
across
panel
purifi
dub
concentr
mm
dub
substanti
inhibit
figur
tabl
doserespons
analysi
use
catalyt
domain
amino
acid
fulllength
enzym
ubiquitinaminomethylcoumarin
ubamc
substrat
confirm
inhibitori
activ
although
potenc
weak
ic
doubledigit
micromolar
rang
figur
isotherm
titrat
calorimetri
itc
use
catalyt
domain
confirm
bind
dissoci
constant
k
mm
figur
tabl
solv
structur
bound
enabl
rapid
structureguid
develop
figur
highli
potent
select
inhibitor
inhibit
catalyt
domain
fulllength
enzym
ic
valu
nm
respect
figur
interact
confirm
use
itc
differenti
scan
fluorimetri
dsf
figur
tabl
consist
improv
biochem
inhibit
compar
k
nm
measur
catalyt
domain
use
itc
figur
tabl
select
assess
panel
purifi
dub
use
ubiquitinrhodamin
ubrho
substrat
retain
excel
select
observ
concentr
mm
exhibit
littl
inhibit
dub
figur
tabl
contrast
enantiom
figur
show
less
potent
inhibit
ic
mm
figur
signific
inhibit
dub
figur
tabl
determin
cocryst
structur
complex
purifi
recombin
catalyt
domain
figur
respect
highresolut
structur
reveal
catalyt
cystein
switch
loop
unproduct
conform
seen
apo
structur
hu
et
al
significantli
differ
unit
cell
dimens
notabl
interact
apo
structur
repres
pdb
facetofac
activ
sitetoact
site
contact
highlight
mutual
complet
insert
side
chain
within
hydrophob
pocket
near
catalyt
cystein
form
helix
loop
interact
present
complex
structur
instead
activ
site
complex
structur
nearli
free
crystal
contact
result
therefor
confirm
relev
propos
autoinhibit
conform
name
crystal
contact
artifact
importantli
complex
structur
reveal
unambigu
electron
densiti
figur
inhibitor
substrat
bind
cleft
lead
activ
site
inhibitor
figur
tabl
occupi
subsit
remov
catalyt
triad
figur
involv
multipl
hydrogen
bond
four
inhibitor
heteroatom
figur
common
compound
specif
quinazolinon
keton
form
hydrogen
bond
peptid
backbon
nitrogen
quinazolinon
cyclic
nitrogen
form
hydrogen
bond
amid
side
chain
tertiari
hydroxi
group
stabil
hydrogen
bond
carboxyl
group
well
peptid
backbon
nitrogen
highli
conserv
among
usp
famili
deubiquitin
enzym
quesada
et
al
hydrogen
bond
ubiquitin
backbon
posit
interact
presum
import
substrat
stabil
hu
et
al
oxygen
atom
piperidin
amid
within
hydroxyl
group
strictli
conserv
dub
famili
side
chain
figur
addit
phenyl
ring
buri
pocket
bound
aromat
ring
aliphat
chain
notabl
side
chain
flip
reveal
hydrophob
pocket
conform
rearrang
also
observ
upon
bind
ubiquitin
hu
et
al
addit
methyl
group
present
carbon
phenyl
ring
involv
multipl
van
der
waal
interact
includ
backbon
phenyl
side
chain
associ
lower
b
factor
loop
atom
buri
except
chlorin
atom
nmethylpiperazin
side
chain
respect
figur
compar
associ
rotat
finger
counterclockwis
around
axi
piperazin
group
crystallograph
studi
complement
hydrogendeuterium
exchang
mass
spectrometri
hdx
ms
monitor
chang
protein
dynam
exchang
backbon
amid
hydrogen
bulk
solvent
accur
measur
upon
inhibitor
bind
iacob
et
al
wale
engen
onlin
digest
perform
peptic
peptid
cover
catalyt
domain
investig
hdx
ms
free
bound
state
figur
protect
loop
figur
confirm
observ
crystal
structur
interact
also
relev
solut
locat
major
chang
protect
exchang
consist
increas
affin
figur
moreov
hdx
ms
result
show
ligandinduc
conform
chang
stabil
distant
activ
site
inhibitor
also
stabilizedprotect
palm
region
near
catalyt
cystein
includ
helic
consist
previous
propos
alloster
regulatori
mechan
faesen
et
al
furthermor
tabl
disord
loop
protect
deuterium
incorpor
suggest
region
becom
order
upon
inhibitor
bind
given
high
degre
select
chemic
seri
surpris
discov
nearli
everi
residu
directli
interact
inhibitor
sever
addit
amino
acid
line
ligand
bind
pocket
conserv
among
usp
famili
dub
figur
show
detail
ligand
interact
diagram
diagram
residu
conserv
defin
usp
possess
equival
residu
accord
mview
classif
figur
brown
et
al
indic
red
box
previou
sitedirect
mutagenesi
studi
show
amino
acid
substitut
sever
posit
abrog
abil
enzym
cleav
dub
substrat
hu
et
al
thu
goal
gain
insight
observ
compound
select
identifi
product
ligand
interact
crystal
structur
primarili
focus
mutagenesi
studi
nonconserv
residu
contain
within
ligand
bind
pocket
seven
mutant
singl
amino
acid
substitut
one
doubl
substitut
gener
figur
substitut
ser
ly
ser
respect
select
base
preval
amino
acid
equival
posit
usp
figur
mutat
amino
acid
replac
alanin
six
eight
mutant
protein
retain
abil
cleav
dub
substrat
ubamc
although
two
significantli
reduc
activ
rel
wildtyp
figur
mutagenesi
studi
carri
parallel
compound
optim
studi
thu
util
assess
inhibitori
activ
chemic
seri
toward
mutant
inhibit
four
activ
mutant
ic
valu
within
severalfold
ic
wildtyp
enzym
figur
howev
highli
resist
exhibit
inhibitori
effect
concentr
mm
compound
figur
uniqu
one
usp
dub
contain
residu
equival
posit
usp
contain
residu
small
side
chain
figur
hand
highli
conserv
among
dub
thu
may
import
determin
select
hydroxypiperidinebas
inhibitor
initi
mutagenesi
studi
carri
use
catalyt
domain
fulllength
confirm
resist
figur
hydrogen
bond
autoinhibit
apo
form
may
requir
stabil
conform
bound
inhibitor
although
complet
understand
molecularlevel
contribut
select
await
structur
studi
studi
support
bind
mode
observ
crystallograph
studi
accur
repres
bind
mode
solut
highresolut
structur
bound
enabl
rapid
optim
potenc
solubl
pharmacolog
properti
compound
lead
detail
four
compound
heteroatom
involv
hydrogenbond
interact
phenyl
ring
buri
hydrophob
pocket
normal
fill
side
chain
substrat
ubiquitin
chloro
atom
solvent
expos
initi
structureact
relationship
investig
figur
focus
establish
import
hydrogenbond
hydrophob
interact
observ
structur
biochem
ic
measur
use
catalyt
domain
ubamc
substrat
inhibit
isol
catalyt
domain
ic
mm
fulllength
protein
ic
mm
compound
hydroxypiperidin
oh
group
remov
replac
cn
respect
exhibit
littl
inhibit
concentr
mm
similarli
remov
amid
carbonyl
abrog
activ
contract
piperidin
ring
occup
hydrophob
pocket
phenyl
ring
confirm
requir
activ
remov
moieti
shorten
linker
hydroxypiperidin
phenyl
result
biochem
ic
mm
contrast
instal
racem
methyl
group
methylen
adjac
phenyl
ring
improv
biochem
potenc
approxim
consist
data
report
patent
exemplifi
explor
import
stereochemistri
methyl
group
prepar
enantiom
reveal
r
stereoisom
approxim
potent
stereoisom
unfortun
investig
abil
bind
inhibit
cell
hamper
poor
solubl
aqueou
buffer
improv
properti
focus
instal
polar
moieti
place
solventexpos
chloro
atom
figur
instal
differ
group
includ
nmethylpiperazin
piperidin
dimethylamin
imidazol
link
quinazolinon
via
short
carbon
chain
amid
bond
linkag
improv
potenc
rel
parent
compound
sever
analog
exhibit
submicromolar
ic
consid
metabol
stabil
addit
paramet
compound
priorit
sinc
probe
suitabl
vivo
studi
would
highli
valuabl
pharmacolog
valid
anim
diseas
model
exhibit
greatest
stabil
presenc
mous
liver
microsom
halflif
min
figur
competit
activitybas
protein
profil
use
dubtarget
activitybas
probe
haubv
hew
et
al
confirm
bound
nativ
figur
treatment
lysat
significantli
block
label
haubv
ic
approxim
mm
valu
repres
signific
improv
compar
concentr
mm
compet
probe
label
figur
experi
irrevers
probe
haubv
compet
occup
revers
inhibitor
measur
cellbas
ic
may
underestim
bind
hemagglutinin
blot
treat
lysat
figur
confirm
high
degre
select
observ
purifi
enzym
panel
measur
gener
toxic
treat
peripher
blood
mononuclear
cell
pbmc
observ
growth
suppress
concentr
mm
follow
hr
treatment
figur
c
analysi
abil
bind
nativ
across
multipl
dose
lysat
use
competit
activitybas
protein
profil
error
bar
repres
sd
n
see
also
figur
achiev
ideal
match
neg
control
compound
use
conjunct
prepar
enantiom
show
less
potent
inhibit
rel
biochem
figur
cellular
target
engag
assay
figur
examin
ontarget
effect
evalu
impact
axi
role
promot
degrad
result
increas
level
document
multipl
model
chauhan
et
al
kon
et
al
cell
treat
level
increas
follow
hr
treatment
concentr
line
ic
nativ
figur
consist
effect
depend
observ
chang
level
protein
across
rang
concentr
compar
inact
enantiom
observ
figur
degrad
observ
system
new
protein
synthesi
block
addit
cycloheximid
figur
necess
block
protein
synthesi
observ
degrad
consist
establish
neg
feedback
loop
involv
protein
transcript
upregul
wu
et
al
similarli
treatment
multipl
myeloma
cell
led
loss
accompani
increas
downstream
tumor
suppressor
previous
report
inhibitor
figur
chauhan
et
al
role
revers
ubiquitin
coordin
wide
rang
cellular
process
includ
proteolysi
dna
repair
receptor
signal
transcript
immun
dub
emerg
new
class
drug
target
although
effort
develop
smallmolecul
probe
dub
studi
role
basic
diseas
biolog
increas
recent
year
effort
produc
limit
number
wellcharacter
optim
inhibitor
dub
enzym
one
wellstudi
dub
report
regul
abund
protein
involv
dnadamag
repair
cellcycl
regul
epigenet
transcript
factor
control
gene
express
notabl
implic
rang
differ
cancer
type
control
import
prolif
process
identifi
promis
diseas
context
deploy
drug
accur
catalog
activ
pertain
promis
liabil
associ
blockad
activ
highli
potent
wellcharacter
probe
compound
sought
present
inhibitor
doubledigit
nanomolar
potenc
toward
exquisit
select
rel
largest
avail
panel
purifi
dub
combin
neg
control
compound
present
set
tool
interrog
biolog
thu
confirm
key
regul
signal
show
promot
degrad
result
increas
level
observ
ic
minimum
fulllength
similar
versu
nm
light
fact
catalyt
domain
effici
augment
presenc
ctermin
ubl
domain
faesen
et
al
may
suggest
kinet
equilibrium
activ
inact
state
fulllength
enzym
rapid
altern
propos
addit
stabl
intermedi
toward
activ
state
repres
flip
result
suggest
fulllength
construct
stabil
intermedi
greater
extent
compar
minim
construct
although
prematur
might
suggest
mechan
ctermin
domain
upregul
catalyt
domain
stabil
flip
repres
one
small
set
mammalian
dub
inhibitor
low
nanomolar
potenc
high
degre
select
rel
dub
dexheim
et
al
ndubaku
tsui
compar
state
dub
field
establish
kinas
field
first
public
phosphoryl
came
year
prior
first
public
ubiquitin
current
state
modul
ubiquityl
via
dub
roughli
drug
phosphoryl
via
kinas
year
ago
cohen
tcherpakov
project
rapid
optim
enabl
larg
success
achiev
highresolut
crystal
structur
lead
compound
complex
establish
seri
biochem
biophys
select
assay
identifi
promis
compound
crystallograph
medicin
chemistri
studi
appli
similar
triag
assay
believ
similar
success
crystallographi
smallmolecul
probe
develop
achiev
dub
famili
member
overal
studi
provid
optim
wellcharacter
smallmolecul
probe
use
studi
role
normal
diseas
biolog
furthermor
lend
consider
valid
notion
dub
class
enzym
potent
select
inhibitor
achiev
dub
famili
proteas
control
level
activ
protein
remov
posttransl
ubiquitin
moieti
particular
interest
drug
discoveri
dub
stabil
diseaselink
protein
includ
mani
target
remain
undrugg
thu
dubtarget
drug
promot
degrad
diseasecaus
protein
repres
novel
strategi
modul
activ
challeng
target
cancer
diseas
progress
develop
potent
select
dub
inhibitor
use
chemic
probe
translat
clinic
slow
howev
note
structureguid
medicin
chemistri
campaign
lack
mammalian
dub
suggest
success
crystallographi
smallmolecul
dub
costructur
enabl
effort
could
significantli
affect
field
succeed
solv
highresolut
xray
crystal
structur
bound
smallmolecul
ligand
seri
costructur
enabl
us
rapidli
improv
potenc
lead
inhibitor
nm
furthermor
show
newli
develop
inhibitor
exhibit
exquisit
select
rel
broad
panel
purifi
cellular
dub
compound
neg
control
stereoisom
promot
degrad
known
substrat
develop
compound
thu
valid
highqual
probe
pharmacolog
interrog
divers
report
function
importantli
work
provid
proof
concept
potent
select
dub
inhibitor
achiev
structur
character
chemic
lead
cognat
dub
target
could
acceler
probe
drug
discoveri
program
detail
method
provid
onlin
version
paper
includ
follow
zhang
xy
varthi
syke
sm
phillip
c
warzecha
c
zhu
w
wyce
thorn
aw
berger
sl
mcmahon
sb
put
cancer
stem
cell
marker
subunit
human
saga
complex
requir
activ
transcript
cellcycl
progress
mol
cell
zhang
l
wang
h
tian
l
li
h
express
correl
poor
prognosi
epitheli
ovarian
cancer
tohoku
j
exp
med
zhao
lang
g
ito
bonnet
j
metzger
e
sawatsubashi
suzuki
e
le
guezennec
x
stunnenberg
hg
krasnov
et
al
tftc
staga
modul
mediat
histon
deubiquitin
coactiv
nuclear
receptor
counteract
heterochromatin
silenc
mol
cell
zinngreb
j
montinaro
peltzer
n
walczak
h
ubiquitin
immun
system
embo
rep
cell
line
cell
obtain
jame
e
bradner
laboratori
authent
cell
obtain
kenneth
c
anderson
laboratori
authent
cell
obtain
jean
zhao
laboratori
authent
cell
grown
dmem
high
glucos
gibco
supplement
heat
inactiv
fetal
bovin
serum
fb
gibco
penicillinstreptomycin
gibco
maintain
humidifi
co
incub
cell
grown
rpmi
gibco
supplement
heat
inactiv
fetal
bovin
serum
fb
gibco
penicillinstreptomycin
gibco
maintain
humidifi
co
incub
primari
cell
obtain
written
consent
approv
danafarb
cancer
institut
institut
review
board
peripher
blood
mononuclear
cell
pbmc
normal
individu
isol
densiti
gradient
centrifug
ficollplaqu
plu
amersham
pharmacia
biotech
ab
uppsala
sweden
minut
follow
two
wash
pb
cell
maintain
rpmi
media
supplement
fb
maintain
humidifi
co
incub
commerci
avail
start
materi
purchas
sigma
aldrich
fisher
scientif
oakwood
chemic
combi
block
reagent
use
receiv
without
purif
known
compound
synthes
accord
publish
literatur
procedur
modif
note
anhydr
solvent
tetrahydrofuran
thf
diethyl
ether
dichloromethan
dcm
dimethyl
formamid
dmf
dimethylsulfoxid
dmso
toluen
phme
purchas
fisher
scientif
use
receiv
necessari
air
moistur
sensit
reaction
carri
inert
atomspher
nitrogen
remov
solvent
accomplish
uchi
rotari
evapor
concentr
done
welch
vacuum
line
labconco
freezon
plu
system
purif
compound
perform
normal
phase
column
chromatographi
use
teledyn
combiflash
chromatographi
system
andor
revers
phase
chromatographi
water
micromass
zq
prepar
system
sunfir
prep
obd
tm
column
puriti
analyz
water
acquiti
uplc
system
analyt
thin
layer
chromatographi
tlc
plate
purchas
fisher
scientif
emd
millipor
tlc
silica
visual
accomplish
irradi
uv
light
nm
hnmr
spectra
record
bruker
arx
mhz
spectromet
cnmr
spectra
record
bruker
arx
mhz
spectromet
sampl
dissolv
cdcl
cd
od
spectra
referenc
residu
solvent
peak
chloroformd
ppm
hnmr
ppm
cnmr
ppm
hnmr
ppm
cnmr
cd
od
ppm
h
nmr
ppm
c
nmr
tetramethylsilan
tm
intern
standard
chemic
shift
multipl
ssinglet
ddoublet
ttriplet
qquartet
mmultiplet
brbroad
peak
coupl
constant
hz
number
proton
mass
spectrometri
lcm
data
obtain
water
acquiti
uplc
system
posit
esi
mode
synthet
procedur
rcl
rno
acid
formamid
mix
pressur
tube
heat
c
overnight
reaction
cool
room
temperatur
solid
suspend
cold
water
collect
vacuum
filtrat
dri
high
vacuum
line
product
cl
isol
light
brown
solid
cl
yield
purif
sodium
hydrid
dispers
miner
oil
dissolv
anhydr
dmso
c
n
trimethylsulfoxonium
iodid
ad
solut
portionwis
addit
complet
mixtur
warm
room
temperatur
stir
ad
portionwis
reaction
mixtur
stir
room
temperatur
hour
c
anoth
hour
mixtur
pour
ice
aqueou
phase
extract
use
etoac
combin
organ
phase
wash
brine
dri
mgso
filter
evapor
reduc
pressur
crude
materi
purifi
flash
column
chromatographi
etoac
hexan
afford
product
yield
rcl
rno
solut
dmf
ad
cs
co
mixtur
heat
c
overnight
reaction
cool
room
temperatur
dilut
etoac
solut
wash
satur
nh
cl
aqueou
phase
extract
etoac
combin
organ
phase
wash
brine
dri
follow
filtrat
evapor
reduc
pressur
crude
materi
purifi
flash
column
chromatographi
etoac
hexan
afford
product
yield
taken
trifluoroacet
acid
tfa
solut
stir
room
temperatur
hour
solut
concentr
reduc
pressur
highvac
overnight
directli
use
start
materi
follow
synthesi
without
purif
rcl
rno
amid
format
hatucatalyz
coupl
reaction
taken
dmf
solut
equival
et
n
ad
carboxyl
acid
premix
hatu
et
n
dmf
concentr
stir
room
temperatur
two
solut
mix
togeth
stir
room
temperatur
hour
reaction
directli
subject
prep
hplc
purif
isol
product
purifi
normal
phase
flash
chromatographi
afford
product
desir
puriti
follow
biolog
test
amid
format
acyl
use
acid
chlorid
taken
dichloromethan
et
n
ad
follow
addit
acetyl
chlorid
reaction
kept
c
stir
hour
reaction
quench
ad
drop
water
follow
immedi
purif
flash
column
chromatographi
isol
product
purifi
hplc
afford
product
yield
reduct
aromat
nitro
group
dissolv
acohetoh
iron
powder
ad
one
portion
reaction
stir
c
hour
iron
powder
remov
filtrat
filtrat
concentr
reduc
pressur
crude
materi
purifi
normal
phase
flash
column
chromatographi
meoh
etoac
follow
revers
phase
hplc
afford
product
yield
instal
solubil
group
dissolv
dichloromethan
et
n
ad
chlorid
dcm
ad
dropwis
reaction
stir
c
quench
addit
drop
water
concentr
reduc
pressur
crude
product
use
next
step
without
purif
crude
materi
last
step
dissolv
dmf
solut
ad
nmethylpiperazin
et
n
reaction
stir
c
hour
solut
directli
subject
revers
phase
hplc
purif
follow
normal
phase
flash
column
chromatographi
meoh
etoac
et
n
afford
product
yield
qd
j
hz
qd
j
hz
c
nmr
mhz
dmso
lcm
esi
ddd
j
hz
j
hz
j
hz
j
hz
j
hz
j
hz
dtd
j
hz
c
nmr
mhz
dmso
lcm
esi
methyl
one
white
solid
yield
h
nmr
mhz
dmso
dd
j
hz
j
hz
ddd
j
hz
j
hz
j
hz
dt
j
hz
ddt
j
hz
ddd
j
hz
c
nmr
mhz
dmso
r
n
methyl
propanamid
offwhit
solid
yield
h
nmr
n
methyl
propanamid
offwhit
solid
yield
hz
dd
j
hz
c
nmr
mhz
dmso
r
dimethylamino
n
methyl
propanamid
offwhit
solid
yield
h
nmr
mhz
n
methyl
propenamid
white
solid
yield
h
nmr
mhz
dmso
j
hz
j
hz
j
hz
j
hz
j
hz
j
hz
j
hz
c
nmr
mhz
dmso
ubamc
assay
mutant
test
activ
ubiquitinamc
assay
presenc
absenc
inhibitor
assay
catalyt
domain
wt
mutant
use
follow
concentr
wt
nm
nm
nm
assay
full
length
wt
mutant
use
nm
variant
preincub
differ
concentr
inhibitor
dmso
control
mm
hepe
mm
edta
um
ovalbumin
mm
dtt
reaction
incub
min
room
temperatur
prior
addit
um
ubiquitinamc
boston
biochem
substrat
initi
rate
reaction
measur
collect
fluoresc
data
one
minut
interv
period
use
clariostar
fluoresc
plate
reader
excit
emiss
wavelength
nm
respect
calcul
initi
rate
valu
plot
inhibitor
concentr
determin
ic
experiment
data
plot
use
prism
graphpad
differenti
scan
fluorimetri
dsf
experi
carri
rtpcr
realtim
system
lifetech
well
plate
total
volum
ul
optim
sypro
orang
dye
concentr
concentr
dmso
invitrogen
compound
dilut
assay
buffer
mm
hepe
ph
mm
nacl
mm
tcep
first
prepar
liquid
handler
formulatrix
addit
dye
perform
also
liquid
handler
seal
plate
heat
cmin
c
c
fluoresc
read
everi
c
tm
valu
determin
minimum
first
deriv
record
fluoresc
intens
versu
temperatur
plot
bind
affin
proteinligand
measur
ad
mm
protein
cell
titrat
mm
ligand
syring
use
microcalorimet
malvern
c
protein
ligand
prepar
within
itc
buffer
contain
mm
hepe
ph
mm
nacl
dmso
data
fit
use
origin
softwar
itc
result
summar
tabl
select
profil
dubprofil
perform
ubiquig
use
manufactur
protocol
mous
liver
microsom
mlm
halflif
measur
perform
scripp
florida
pharmacolog
core
accord
protocol
biochem
curv
statist
analys
produc
use
prism
graphpad
softwar
structur
file
coordin
deposit
pdb
access
number
